TAGS: Sealants
Baxter International Inc. has completed the acquisition of Seprafilm Adhesion Barrier and related assets from Sanofi for 350 million USD to expand hemostat and sealant portfolio. The Seprafilm product family, which is used as an adjunct to reduce the incidence, extent and severity of adhesions in certain pelvic and abdominal surgeries, currently has a global commercial presence in the U.S., Japan, China, South Korea and France, among other countries.
Reduction in Adhesion Severity Post Surgery
"
We are excited to bring Seprafilm products, alongside our leading hemostat and sealant portfolio, to our surgeon and hospital customers around the world," said Wil Boren, general manager, Baxter's Advanced Surgery business.
"
As we begin the integration process, our dedicated surgery commercial team is focused on working with customers and distributors to ensure a smooth transition," added Boren.
Seprafilm has been more extensively evaluated than any other adhesion barrier and has been found to significantly reduce the incidence, extent, and severity of adhesions following abdominopelvic surgery. Numerous prospective, randomized, controlled, clinical studies have demonstrated the efficacy of Seprafilm.
Adhesion prevention products, hemostats and sealants are important tools surgeons use to manage intraoperative bleeding and reduce adhesions. Adhesions can occur in any surgery when scar tissue develops and binds to nearby tissue. Adhesions can be a source of major post-surgical complications and often require revision, or a second surgery to remove the adhesions.
Source: Baxter